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Abstract
Background:  The hetero-glycopeptide intermediate staphylococci is considered to be the
precursor of glycopeptide intermediate staphylococci especially vancomycin intermediate
Staphylococcus aureus (VISA). For this purpose, we aimed to investigate the heterogeneous
resistance to glycopeptide and their frequencies in 135 Staphylococcus strains.
Methods: Heterogeneous resistance of Staphylococcus strains was detected by inoculating the
strains onto Brain Heart Infusion agar supplemented with 4 mg/L of vancomycin (BHA-V4). Agar
dilution method was used for determining MICs of glycopeptides and population analysis profile
was performed for detecting frequency of heterogeneous resistance for the parents of selected
strains on BHA-4.
Results: Eight (6%) out of 135 Staphylococcus strains were exhibited heterogeneous resistance to
at least one glycopeptide. One (1.2%) out of 81 S. aureus was found intermediate resistance to
teicoplanin (MIC 16 mg/L). Other seven strains were Staphylococcus haemolyticus (13%) out of 54
coagulase negative staphylococci (CoNS). Six of the seven strains were detected heterogeneously
reducing susceptibility to vancomycin (MICs ranged between 5–8 mg/L) and teicoplanin (MICs
ranged between 32–64 mg/L), and one S. haemolyticus was found heterogeneous resistance to
teicoplanin (MIC 32 mg/L). Frequencies of heterogeneous resistance were measured being one in
106 – 107 cfu/ml. MICs of vancomycin and teicoplanin for hetero-staphylococci were determined as
2–6 folds and 3–16 folds higher than their parents, respectively. These strains were isolated from
six patients (7%) and two (4%) of health care wokers hands. Hetero-VISA strain was not detected.
Conclusion: Heterogeneous resistance to glycopeptide in CoNS strains was observed to be
significantly more emergent than those of S. aureus strains (vancomycin P 0.001, teicoplanin, P
0.007). The increase MICs of glycopeptide resistance for subpopulations of staphylococci
comparing with their parents could be an important clue for recognizing the early steps in the
appearance of VISA strains. We suggested to screen clinical S. aureus and CoNS strains,
systematically, for the presence of heterogeneously resistance to glycopeptide.
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Background
Since the first report published from Japan in 1997 on
vancomycin-intermediate (MIC 8–16 mg/L) Staphylococ-
cus aureus (VISA)[1] and studies from different countries,
suggested that the emergence of glycopeptide resistance
among staphylococci is a global issue [2]. Survey of resist-
ance to glycopeptide indicates that there are two types of
resistances. The first type is homogeneous resistance
which occurs as a result of thickening in the cell wall, such
as being in VISA strain [3]. The other homogeneous resist-
ance was reported from Michigan in June 2002 [4] in
which MIC of vancomycin for the S. aureus strain was
found ≥  32 mg/L and regarded as the first vancomycin
resistance S. aureus (VRSA). VRSA strain has vanA gene of
enterococci which explains the origin of VRSA strain [5].
The main difference between the VISA and VRSA strains is
that the later could transfer the glycopeptide resistance
among the strains by plasmids. Homogeneous resistance
could be determined by conventional methods as
described by the National Committee for Clinical Labora-
tory Standards (NCCLS) [6]. The second type is heteroge-
neous resistance, which was described firstly by
Hiramatsu et al [1] from Japan in 1997, and it is repre-
sented with strain Mu3 (hetero-VISA). Mu3 strain has
been isolated from an old man with pneumonia who did
not give any response to vancomycin therapy, although
MIC of Mu3 was 4 mg/L it has been containing a mutant
subpopulation of cells having intermediate resistance to
vancomycin (MIC 8 mg/L).
It is difficult to detect heteroresistance by NCCLS methods
because the concentration of bacterial population which
was advised by NCCLS (5 × 105 cfu /mL) is not sufficient
to detect heteroresistance (1 in 106 cfu/mL). Population
analysis method is the most common screening method
for the detection of heteroresistant staphylococci [1].
Depending on many studies hetero-VISA is precursor
strain for VISA [7]. A growing concern over recent reports
from many countries suggests that the hetero-VISA is prev-
alent and responsible for the failure of vancomycin ther-
apy [5]. Clonal spread of these strains via hands of Health
Care Workers (HCW) has also been reported [8]. Beacuse
of low virulance of CoNS, they have been dismissed as
being culture contaminants in the past, however, in recent
years they have been assumed of greater importance as
true pathogens and the emergence of strains with
decreased levels of susceptibility to vancomycin and teico-
planin have been noticed in many studies reviewed by
Cercenado et al [9]. Istanbul University hospital is a large
hospital with 1500 bed capacity, we aimed to determine
heterogeneously resistance to vancomycin and teico-
planin in S. aureus and CoNS strains for the first time in
Turkey.
Methods
Strains
A nonrepetitive 135 Staphylococcus strains were collected
from September 2001 to April 2002 from the Faculty of
Medicine of the Department of Microbiology and Clinical
Microbiology of the University of Istanbul in Turkey.
These were 87 strains (73 S. aureus and 14 CoNS) which
were clinical or colonized isolates of the skin of different
body sites of the hospitalized patients, and 48 strains (40
CoNS and 8 S. aureus) colonized on the skin of the hands
of HCWs. CoNS strains were identified to the species level
by standard biochemical procedures [10]. The species dis-
tribution of CoNS were as follows: S. haemolyticus 18
(33.3%), S. epidermidis 10 (18.5%), S. simulans 6 (11.1%),
S. schleiferi 6 (11.1%), S. lugdunensis 3 (5.5%), S. arlettae 3
(5.5%), S. xylosus 3 (5.5%), S. hominis 3 (5.5%), S. capitis
1 (1.8 %), and S. warneri 1 (1.8%). Staphylococcus aureus
ATCC 29213 was used as control strain for determining
MICs of glycopeptides. Heterogeneous VISA strain Mu3
was used as control in population analysis profile
method.
MICs criteria of Glycopeptides
MICs were evaluated according to the NCCLS breakpoints
for Staphylococcus  strains [11] and were as follows: For
vancomycin ≤  4 mg/L as susceptible, 8 – 16 mg/L as inter-
mediate, and ≥  32 mg/L as resistance. For teicoplanin: ≤  8
mg/L as susceptible, 16 mg/L as intermediate and ≥  32
mg/L as resistance.
Detection of Staphylococcus strains with hetero-reduced 
susceptibility to vancomycin
This method was applied as described previously by Hira-
matsu et al [1]. Briefly, overnight cultures were adjusted to
0.5 McFarland turbidity and 10 µl of the suspension was
inoculated onto Brain Heart Infusion agar (BHA) (BBL;
Becton Dickinson and Company, Cockeyvilles, USA)
plates containing 4 mg/L of vancomycin (Sigma, chemical
Inco, Germany) (BHA-V4), and incubated at 37°C for 48
hours. If a countable number (one to 30) of colonies
grew, the strain was considered to have potential heterore-
sistance to glycopeptide and was confirmed with popula-
tion analysis profile method. The strain was accepted as
susceptible to vancomycin if an obvious growth was not
seen on the inoculated plate.
Population analysis profile method
This method was used for detecting of staphylococci sub-
clones intermediate or resistant to glycopeptide. For this
purpose, the parents of the selected colonies on BHA-V4
were used and the method was performed as previously
defined by Hiramatsu et al [1]. A 50-µl aliquot of the over-
night isolates and control strain (Mu3) in Brain Heart
Infusion (BHI) broth were adjusted to optical density of
578 (108 cfu/ml) and serial 10-fold dilutions were spreadBMC Infectious Diseases 2005, 5:31 http://www.biomedcentral.com/1471-2334/5/31
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over two different BHA plates, one containing vancomy-
cin at concentrations ranging from 1 to 10 mg/L (ten dilu-
tions), and the other containing teicoplanin (Gruppo
Lepetit S.P.A, Italy) at concentrations ranging from 1 to 64
mg/L (two fold dilutions). After incubation at 37°C for 48
hours, the number of viable cells were calculated and plot-
ted on a semi-logarithmic scale. Heterogeneous Resistant
Staphylococci was defined as any screen-positive strain
which contained subpopulations with MIC > 4 mg/L for
vancomycin or ≥  16 µg/ml for teicoplanin at a frequency
of 1 in 106 cfu/mL or higher.
Detection MICs of vancomycin and teicoplanin
MICs were determined for the parents of strains grown on
BHA-V4 by using cation-adjusted MHA (Oxoid, Unipath
LTD, Hampshire, England) and two fold increments of
vancomycin at concentrations ranging from 0.25–32 mg/
L and teicoplanin at concentrations ranging from 0.25–
128 mg/L and the agar dilution method was performed
according to the NCCLS [6].
Patients Medical Record
Records of patients who had colonized or infected with
Staphylococcus strains with decreased susceptibility to glyc-
opeptides were reviewed and data related to the patients
age, gender, ward, underlying disease, specimen, duration
of hospitalization and previous treatment with glycopep-
tides were evaluated.
Statistical analysis
Fisher's test was used for comparing of glycopeptide resist-
ance between S. aureus and CoNS strains.
Results
Detection of staphylococci with reduced susceptibility to 
glycopeptides
Nine (7%) out of 135 Staphylococcus strains grew on BHA-
V4 screening plates. Two of these strains were found as
being methicillin susceptible S. aureus (MSSA, 4502 and
4503) and other seven strains were found as being methi-
cillin resistant CoNS (MRCoNS) (strains from 4504 to
4510).
MICs of vancomycin and teicoplanin of strains grew on 
BHA-V4
MICs of vancomycin and teicoplanin for the parents of
subclones were as follows: for each of 4502 and 4503
strains were found being susceptible (1 mg/L), for seven
MRCoNS strains were found susceptible to vancomycin
and ranged between 1–4 mg/L. MICs of teicoplanin were
found being intermediately susceptible (16 mg/L) for two
MRCoNS (4508, 4510) strains and susceptible (1 to 8 mg/
L) for another five strains.
Population analysis profile
Although S. aureus no 4502 grew on BHA-4, its sublones
were susceptible to vancomycin (MIC 4 mg/L) and teico-
planin (MIC 8 mg/L). This strain was not accepted as het-
erogeneous strain, whereas those of S. aureus 4503 were
susceptible to vancomycin (MIC 3 mg/L) and resistant to
teicoplanin (MIC 32 mg/L) and the strain was hetero-
teicoplanin resistant S. aureus (TRSA). MICs for subclones
of seven MRCoNS (all were S. haemolyticus) of vancomy-
cin (except strain 4506: MIC 4 mg/L) were reduced sus-
ceptibility and varied between 5–8 mg/L, and all were
resistant to teicoplanin (MICs were ranged between 32–
64 mg/L). Heterogeneous frequencies in staphylococci
strains were observed 1 in 106 – 107cfu/ml (Fig. 1, 2, 3, 4).
Therefore, heteroresistance to glycopeptide antibiotics
was found to be one (1.2%) out of 81 S. aureus strains and
seven (13%) out of 54 CoNS strains. Heteroresistance to
glycopeptide was higher in S. haemolyticus (39%) and it
was found as being the only species among CoNS that has
showed heteroresistance to glycopeptide.
Glycopeptide resistance in clinical and colonized strains
Six (7%) out of 87 patients and two (4%) out of 48 HCWs
hands isolates displayed heterogeneous resistance to at
least one glycopeptides. Only one strain (4503) out of
eight S. aureus strains colonizing HCWs hand's skin was
hetero-intermediate resistance to teicoplanin, and none of
the 73 screened clinical S. aureus strains had reduced sus-
ceptibilty to glycopeptides. For CoNS strains, six out of 14
patients isolates and one out of 40 HCWs hand skin
strains were hetero-resistant to vancomycin and teico-
planin with the exception of 4506 strain; it was suscepti-
ble to vancomycin and resistant to teicoplanin (Table 1).
Discussion
Heterogeneous resistance to teicoplanin among S. aureus
strains was very low (1.2%), whereas this resistance
among MRCoNS was higher (13%). Using vancomycin
was licensed in 1994 in Turkey and preceded teicoplanin
about two years. From this point of view, the expectation
was to detect Staphylococcus  strains with vancomycin
resistance more than teicoplanin resistance. But our
results have shown that seven S. haemolyticus were resist-
ant to teicoplanin (MIC ≥  32 mg/L) and one S. aureus
strain has an intermediate resistance to teicoplanin (MIC
16 mg/L), whereas resistance to vancomycin in the same
eight strains subclones was increased mildly above the
susceptible range (4 m/L) in six strains, and intermediate
range (8 mg/L) in two strains. It is hard to link between
the glycopeptide use and appearance of resistance to this
antibiotic group in our strains, because except in two
strains (4506 and 4507), no previous treatment with any
glycopeptide was found through viewing the medical
reports of the patients colonized or infected with these
strains. On the other hand, the MICs of vancomycin evenBMC Infectious Diseases 2005, 5:31 http://www.biomedcentral.com/1471-2334/5/31
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for these two strains were 4 mg/L for the former and 5 mg/
L for late strain. The selective pressure, independently
from the treatment with glycopeptide, could be the major
factor in the heterogeneous resistance among strains
(Table 1).
Historically,  S. aureus acquired teicoplanin resistance
before it acquired vancomycin resistance. Teicoplanin
resistance is frequently accompanied with a small increase
in vancomycin resistance [12]. Shlaes et al [13], demon-
strated that PBP2 is overproduced in a TRSA mutant strain
(MIC 16 mg/L) compared with its parent strain. Over-pro-
duction of PBP2 is also observed in the hetero-VISA strain
Mu3 which is resistant to teicoplanin. Most of the studies
on glycopeptide resistance mechanisms were done with S.
aureus strains and it may be also true for CoNS strains; but,
more studies are needed.
Species variation has been detected in vancomycin suscep-
tibility of CoNS, according to many studies [14-16]. This
resistance was more common in S. haemolyticus and S. epi-
dermidis. In this study, we also obtained similar results, in
which S. haemolyticus was the only species revealed with
high resistance (39%) to glycopeptide among ten differ-
ent species. Indeed there is not a sufficient explanation
which relates directly the glycopeptide resistance and spe-
cies phenomenon.
A survey of hetero-VISA revealed differences in the preva-
lence of hetero-VISA between the countries and even
Population analysis of two S. aureus strains (4502,4503) grew on BHA-V4 Figure 1
Population analysis of two S. aureus strains (4502,4503) grew on BHA-V4. MICs of vancomycin for subclones were susceptible 
(3–4 mg/L).
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between university and nonuniversity hospitals in the
same country. In Japan after the first report on hetero-
VISA in 1997, Hiramatsu et al [1] have reported a result of
hetero-VISA as 3%, however, no hetero-VISA strain was
found in a study conducted in the same year by Ike et al
[17] on 6,625 S. aureus of university and nonuniversity
hospitals strains. Prevalence of heteroVISA strains in the
other European countries like Italy, Germany, France,
Netherland were reported as 1.1%, 0.21%, 0.6%, 6%,
respectively, [18-21] and in Thailand and Korea as 1.93%
and 0.54%, respectively [22,23]. We did not isolate heter-
oVISA strain, but we detected heteroTRSA. Heterogeneous
resistances to vancomycin and teicoplanin among CoNS
were found to be 11% and 13%, respectively, and higher
than those obtained by Gruneberg et al [24], a European
collaborative study on 1594 CoNS from bloodstream
infections, and they found that all of the isolates were sus-
ceptible to vancomycin and only 0.7% of them were
resistant to teicoplanin.
Examination of six heteroMRCoNS showed that three
strains colonized the skin of different body sites of immu-
nocompromised patients and three others were isolated
from clinical specimens (Table 1). The MICs of vancomy-
cin for these strains were varied between the susceptible
and intermediate ranges, whereas teicoplanin was in the
resistance ranges. The strain no 4509 which was isolated
from the hand skin of HCW was intermediate resistant to
vancomycin (7 mg/L) and resistant to teicoplanin (64 mg/
L). According to the Spanish studies, 0.55 % of CoNS
strains exhibiting either decreased levels of susceptibility
or true resistance to teicoplanin [9].
Two (4%) out of 48 HCWs hands were colonized with
two types of strains, S. aureus 4503, which was the only
intermediate resistant to teicoplanin (MIC 16 mg/L) as
well as S. haemolyticus 4509. The last strain was an impor-
tant strain because vancomycin MIC for its
Population analysis of two S. aureus strains grew on BHA-V4 Figure 2
Population analysis of two S. aureus strains grew on BHA-V4. MICs of teicoplanin for subclones of MSSA-4502 were susceptible 
(8 mg/L) and for MSSA-4503 were resistant (32 mg/L).
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subpopulations was closely to intermediate (7 mg/L) and
also resistant to teicoplanin. The role of these two HCW
for spreading of the strains was not investigated.
The treatment failures due to the selection of teicoplanin
resistant mutants have been reported following treatment
of  S. aureus infections with teicoplanin [12,13,25]. A
study made by Wong et al [26], showed that the patients
infected by heteroresistant strains have higher mortality
rates than the patients infected by sensitive isolates. Other
studies on treatment failure associated with heterogene-
ous VISA have been reported as well [1,5,27]. Our three
infected patients with hetero-CoNS have been treated suc-
cessfuly with vancomycin, on the other hand, death of the
third patient was not related to the infection (Table 1).
Although the number of S. aureus and CoNS strains
included in this study were low, and it is not enough to
predict the prevalence. This first study from one of the
four largest university hospitals from Turkey may give an
idea regarding the status of resistance to glycopeptide
among Staphylococcus strains, and as a preliminary study
need to be followed up with other studies.
Conclusions
Our study showed that CoNS strains have an emerging
heteroresistance for both vancomycin and teicoplanin
Population analysis of MRCoNS strains grew on BHA-V4 Figure 3
Population analysis of MRCoNS strains grew on BHA-V4. MICs of vancomycin for six MRCoNS strains subclones (4504, 4505, 
4507, 4508,4509,4510) were reduced (5–8 mg/L) and for one strain (4506) subclones were susceptible (4 mg/L).
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Population analysis of seven MRCoNS strains (4504–4510) grew on BHA-V4 Figure 4
Population analysis of seven MRCoNS strains (4504–4510) grew on BHA-V4. MICs of teicoplanin for these strains subclones 
were resistant (32–64 mg/L).
Table 1: Clinical features of patients infected or colonized with MRCoNS with reduced susceptibility to glycopeptides
Patients 
Strain No
Age/sex Ward Clinical 
feature
Underlying 
disease
Specimen Duration of 
hospitalizati
on (days)
Previous 
treatment 
with 
glycopeptide 
(days)
Treatment 
with 
glycopeptide 
(days)
Clinical 
outcome
4504 46/F Infectious 
Diseases
Pneumonia Trauma tracheal 
aspiration 
fluid
20 No vancomycin 
(14)
Improved
4505 33/M Haematology Septicemia CML Groin skin 27 No No NT
4506 44/M Haematology Septicemia AML Abdominal 
wall skin
46 vancomycin 
(20)
No NT
4507 46/F Haematology Septicemia ALL Axilla skin 60 vancomycin 
(10)
No NT
4508 26/M SICU Septicemia Trauma and 
Fracures Of 
mandibula 
and maxilla
Blood 31 No vancomycin 
(10)
Improved
4510 75/F Infectious 
Diseases
Septicemia Surgical 
operation 
of Colon
Blood 6 No vancomycin 
(14)
Death not 
related to 
staphylococ
cal infection
Abbreviations: M, male; F, female; CML, chronic myelogenous leukemia; AML, acute myelogenous leukemia; AML, acute lymphocytic leukemia; 
SICU, surgical intensive care unit; NT, staphylococci skin colonization not treated.
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more than those of S. aureus strains and this difference
was found to be significant (P = 0.001, P = 0.007 for van-
comycin and teicoplanin, respectively). We suggested to
screen clinical S. aureus and CoNS strains, systematically,
in case of the presence of heterogeneously resistance to
glycopeptide to avoid treatment failure or any nosocomial
outbreaks in the future.
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